Leucylleucine methyl ester | CAS#13022-42-9

MedKoo Cat#: 529916 | Name: Leucylleucine methyl ester

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Leucylleucine methyl ester is a drug potentially for the treatment of Graft-Versus-Host-Disease.

Chemical Structure

Leucylleucine methyl ester

CAS#13022-42-9 (methyl ester)

Theoretical Analysis

MedKoo Cat#: 529916

Name: Leucylleucine methyl ester

CAS#: 13022-42-9 (methyl ester)

Chemical Formula: C13H26N2O3

Exact Mass: 258.1900

Molecular Weight: 258.36

Elemental Analysis: C, 60.44; H, 10.14; N, 10.84; O, 18.58

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

13022-42-9 (methyl ester) 2883-36-5 (free)

Synonym

LLME; LeuLeuOMe

IUPAC/Chemical Name

L-Leucine, N-L-leucyl-, methyl ester

InChi Key

AJMOLNFDYWTVQW-QWRGUYRKSA-N

InChi Code

InChI=1S/C13H26N2O3/c1-8(2)6-10(14)12(16)15-11(7-9(3)4)13(17)18-5/h8-11H,6-7,14H2,1-5H3,(H,15,16)/t10-,11-/m0/s1

SMILES Code

CC(C)C[C@@H](C(OC)=O)NC([C@H](CC(C)C)N)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

	Solvent	mg/mL	mM	comments
Solubility
	Soluble in DMSO	0.0	0.00

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 258.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Hsieh MH, Varadi G, Flomenberg N, Korngold R. Leucyl-leucine methyl ester-treated haploidentical donor lymphocyte infusions can mediate graft-versus-leukemia activity with minimal graft-versus-host disease risk. Biol Blood Marrow Transplant. 2002;8(6):303-15. PubMed PMID: 12108916. 2: Ohlin M, Danielsson L, Carlsson R, Borrebaeck CA. The effect of leucyl-leucine methyl ester on proliferation and Ig secretion of EBV-transformed human B lymphocytes. Immunology. 1989 Apr;66(4):485-90. PubMed PMID: 2541070; PubMed Central PMCID: PMC1385146. 3: Mowat AM, Leck PA. Generalized toxicity of L-leucyl-leucine-methyl ester for lymphocyte functions. Immunology. 1990 Apr;69(4):564-9. PubMed PMID: 2335375; PubMed Central PMCID: PMC1385630. 4: Pechhold K, Kabelitz D. Human peripheral blood gamma delta T cells are uniformly sensitive to destruction by the lysosomotropic agents leucine methyl ester and leucyl leucine methyl ester. Eur J Immunol. 1993 Feb;23(2):562-5. PubMed PMID: 8436187. 5: Thiele DL, Geissler GH, Williams FH, Lipsky PE. The role of leucyl-leucine methyl ester-sensitive cytotoxic cells in skin allograft rejection. Transplantation. 1992 Jun;53(6):1334-40. PubMed PMID: 1604489. 6: Thiele DL, Lipsky PE. The action of leucyl-leucine methyl ester on cytotoxic lymphocytes requires uptake by a novel dipeptide-specific facilitated transport system and dipeptidyl peptidase I-mediated conversion to membranolytic products. J Exp Med. 1990 Jul 1;172(1):183-94. PubMed PMID: 1972727; PubMed Central PMCID: PMC2188150. 7: Thiele DL, Calomeni JA, Lipsky PE. Leucyl-leucine methyl ester treatment of donor cells permits establishment of immunocompetent parent----F1 chimeras that are selectively tolerant of host alloantigens. J Immunol. 1987 Oct 1;139(7):2137-42. PubMed PMID: 3309052. 8: Thiele DL, Charley MR, Calomeni JA, Lipsky PE. Lethal graft-vs-host disease across major histocompatibility barriers: requirement for leucyl-leucine methyl ester sensitive cytotoxic T cells. J Immunol. 1987 Jan 1;138(1):51-7. PubMed PMID: 2946780. 9: Chen KW, Bezbradica JS, Groß CJ, Wall AA, Sweet MJ, Stow JL, Schroder K. The murine neutrophil NLRP3 inflammasome is activated by soluble but not particulate or crystalline agonists. Eur J Immunol. 2016 Apr;46(4):1004-10. doi: 10.1002/eji.201545943. PubMed PMID: 27062120. 10: Hughes CS, Colhoun LM, Bains BK, Kilgour JD, Burden RE, Burrows JF, Lavelle EC, Gilmore BF, Scott CJ. Extracellular cathepsin S and intracellular caspase 1 activation are surrogate biomarkers of particulate-induced lysosomal disruption in macrophages. Part Fibre Toxicol. 2016 Apr 23;13:19. doi: 10.1186/s12989-016-0129-5. PubMed PMID: 27108091; PubMed Central PMCID: PMC4842290. 11: Demizu Y, Yamashita H, Doi M, Misawa T, Oba M, Tanaka M, Kurihara M. Topological Study of the Structures of Heterochiral Peptides Containing Equal Amounts of l-Leu and d-Leu. J Org Chem. 2015 Sep 4;80(17):8597-603. doi: 10.1021/acs.joc.5b01541. PubMed PMID: 26274390. 12: Železnik TZ, Kadin A, Turk V, Dolenc I. Aspartic cathepsin D degrades the cytosolic cysteine cathepsin inhibitor stefin B in the cells. Biochem Biophys Res Commun. 2015 Sep 18;465(2):213-7. doi: 10.1016/j.bbrc.2015.07.155. PubMed PMID: 26239660. 13: Hagforsen E, Paivandy A, Lampinen M, Weström S, Calounova G, Melo FR, Rollman O, Pejler G. Ablation of human skin mast cells in situ by lysosomotropic agents. Exp Dermatol. 2015 Jul;24(7):516-21. doi: 10.1111/exd.12699. PubMed PMID: 25808581. 14: Katsnelson MA, Rucker LG, Russo HM, Dubyak GR. K+ efflux agonists induce NLRP3 inflammasome activation independently of Ca2+ signaling. J Immunol. 2015 Apr 15;194(8):3937-52. doi: 10.4049/jimmunol.1402658. PubMed PMID: 25762778; PubMed Central PMCID: PMC4390495. 15: Brojatsch J, Lima H Jr, Palliser D, Jacobson LS, Muehlbauer SM, Furtado R, Goldman DL, Lisanti MP, Chandran K. Distinct cathepsins control necrotic cell death mediated by pyroptosis inducers and lysosome-destabilizing agents. Cell Cycle. 2015;14(7):964-72. doi: 10.4161/15384101.2014.991194. PubMed PMID: 25830414; PubMed Central PMCID: PMC4614982. 16: Shemesh A, Wang Y, Yang Y, Yang GS, Johnson DE, Backer JM, Pessin JE, Zong H. Suppression of mTORC1 activation in acid-α-glucosidase-deficient cells and mice is ameliorated by leucine supplementation. Am J Physiol Regul Integr Comp Physiol. 2014 Nov 15;307(10):R1251-9. doi: 10.1152/ajpregu.00212.2014. PubMed PMID: 25231351; PubMed Central PMCID: PMC4233288. 17: Brojatsch J, Lima H, Kar AK, Jacobson LS, Muehlbauer SM, Chandran K, Diaz-Griffero F. A proteolytic cascade controls lysosome rupture and necrotic cell death mediated by lysosome-destabilizing adjuvants. PLoS One. 2014 Jun 3;9(6):e95032. doi: 10.1371/journal.pone.0095032. PubMed PMID: 24893007; PubMed Central PMCID: PMC4043491. 18: Butinar M, Prebanda MT, Rajković J, Jerič B, Stoka V, Peters C, Reinheckel T, Krüger A, Turk V, Turk B, Vasiljeva O. Stefin B deficiency reduces tumor growth via sensitization of tumor cells to oxidative stress in a breast cancer model. Oncogene. 2014 Jun 26;33(26):3392-400. doi: 10.1038/onc.2013.314. PubMed PMID: 23955077. 19: Maejima I, Takahashi A, Omori H, Kimura T, Takabatake Y, Saitoh T, Yamamoto A, Hamasaki M, Noda T, Isaka Y, Yoshimori T. Autophagy sequesters damaged lysosomes to control lysosomal biogenesis and kidney injury. EMBO J. 2013 Aug 28;32(17):2336-47. doi: 10.1038/emboj.2013.171. PubMed PMID: 23921551; PubMed Central PMCID: PMC3770333. 20: Lima H Jr, Jacobson LS, Goldberg MF, Chandran K, Diaz-Griffero F, Lisanti MP, Brojatsch J. Role of lysosome rupture in controlling Nlrp3 signaling and necrotic cell death. Cell Cycle. 2013 Jun 15;12(12):1868-78. doi: 10.4161/cc.24903. PubMed PMID: 23708522; PubMed Central PMCID: PMC3735701.